Arch Oncology, Inc
4320 Forest Park Avenue
Suite 304
St. Louis
MO
63108
United States
Website: http://www.archoncology.com/
About Arch Oncology, Inc
Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of cancer. Anti-CD47 therapies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer. Arch Oncology has developed a functionally diverse antibody platform and is advancing a novel anti-CD47 antibody to the clinic that not only acts as an immune checkpoint inhibitor, but also selectively kills tumor cells (non ADCC). The team is a highly motivated group of experienced scientists and emphasizes a collaborative approach. Arch Oncology is funded by top-quality venture capital investors and is advancing its lead mAb to the clinic currently.
26 articles about Arch Oncology, Inc
-
Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma
1/21/2022
Arch Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to AO-176 on January 3rd , 2022, for the treatment of relapsed/refractory multiple myeloma (r/r MM).
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments
8/2/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced several key leadership appointments in newly created positions, including Louie Naumovski, M.D., Ph.D., as Chief Medical Officer, Amit Agarwal M.D., Ph.D., as Senior Vice President, Clinical Development, and Steve DeMattos as Senior Vice President, Clinical Operations.
-
The race is on in the CD47 field, and Brisbane-based player Arch Oncology just upped the bet with a $105 million Series C raise.
-
Arch Oncology Secures $105 Million Series C Financing
4/27/2021
Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies
-
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
4/10/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, announced the presentation of new preclinical data on AO-176 in pediatric acute lymphoblastic leukemia during a late-breaking poster presentation at the AACR Annual Meeting 2021.
-
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
4/7/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member
-
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021
3/10/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the American Association for Cancer Research (AACR) Annual Meeting 2021.
-
Arch Oncology to Participate in Upcoming Conferences
2/16/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences:
-
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors
2/9/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck, known as MSD outside of the United States and Canada.
-
Arch Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
1/6/2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that Julie Hambleton, M.D., the Company’s Interim President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. Event: 39th Annual J.P. Morgan Healthcare Conference Date: January 14, 2021 12:10-12:35 pm ET About Arch Oncology A
-
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma
12/7/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that the first patient has been dosed in a new Phase 1/2 clinical trial for AO-176 in relapsed/refractory multiple myeloma.
-
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
12/6/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, announced the presentation of new preclinical data on AO-176 at the ASH Annual Meeting 2020.
-
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer
11/16/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Ronald Krasnow, Esq. as Chief Operating Officer. In this newly created position, Mr. Krasnow will report to Julie Hambleton, M.D., Arch Oncology’s Interim President and Chief Executive Officer. “Ron is a legal and strategy executive with a unique breadth of e
-
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020
11/9/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020.
-
Arch Oncology to Present at Upcoming Conferences
10/26/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced upcoming presentations at conferences and medical meetings: Investor Conference: Event: Stifel 2020 Annual Healthcare Conference Date: November 17, 2020, 4:40 pm ET Medical and Scientific Meetings: Event: Macrophage-dir
-
Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors
10/5/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the expansion of AO-176’s clinical development into a Phase 1/2 chemotherapy combination trial for
-
Arch Oncology Announces Formation of Scientific Advisory Board
6/22/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts. The SAB will work closely with Arch Oncology
-
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors
4/21/2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.
-
Arch Oncology Appoints Drew Dennison to Board of Directors
8/12/2019
Drew Dennison is Managing Director at Lightchain Capital, LLC, the family office for Scottrade Founder and former Chief Executive Officer Rodger Riney.